Alaska Permanent Fund’s Alexion Pharmaceuticals ALXN Stock Holding History

Alaska Permanent Fund’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,400	Closed	-$2.65M	–	228
2021 Q2	$2.65M	Sell	14,400 -5,500	-28%	-$944K	0.05%	47
2021 Q1	$3.04M	Hold	19,900	–	–	0.06%	146
2020 Q4	$3.11M	Hold	19,900	–	–	0.06%	73
2020 Q3	$2.28M	Buy	19,900 +10,380	+109%	+$1.12M	0.04%	66
2020 Q2	$1.07M	Hold	9,520	–	–	0.02%	52
2020 Q1	$855K	Buy	+9,520	New	+$934K	0.01%	51

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Alaska Permanent Fund's ALXN Position: Q3 2021 in Review

Alaska Permanent Fund sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 14,400 shares — an estimated $2.65M sold.

Alaska Permanent Fund first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $3.11M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Alaska Permanent Fund reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Alaska Permanent Fund sold 14,400 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.65M.
Alaska Permanent Fund first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Alaska Permanent Fund's Alexion Pharmaceuticals position peaked at $3.11M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Alaska Permanent Fund's 13F filing for Q3 2021, filed 9 Nov 2021.